To study the potential role of Platelet Rich Plasma (centrifuged whole blood) as a therapeutic modality in Melasma (patchy brown discoloration of face)
- Conditions
- Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue
- Registration Number
- CTRI/2020/09/027525
- Lead Sponsor
- Dr RPG Medical College Kangra
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Age > 18 years
Non Pregnant and Non lactating women
Patients not taking oral contraceptives.
Patients with no history of chronic liver disease, thromboembolism, bleeding disorders, and abnormal coagulation profile; on antiplatelet, anticoagulant or systemic chemotherapy.
Patients with no history of hypertrophic scars or keloids, recurrent herpes infection or current cutaneous infection
Patients with no history psychological disorders
Patients who have not taken any other melasma therapy within last 3 months.
Age less than 18 years
Pregnant and lactating women
Patients taking oral contraceptives
Patients with history of chronic liver disease, thromboembolism, bleeding disorders, and abnormal coagulation profile; on antiplatelet, anticoagulant or systemic chemotherapy
Patients with history of hypertrophic scars or keloids, recurrent herpes infection or current cutaneous infection
Patients with psychological disorders
Patients having unrealistic expectation from the treatment
Patients who have taken any other melasma therapy within last 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The Modified Melasma Assessment Severity Index (mMASI) score will be the primary outcome measure.Timepoint: It will be determined during the start of treatment (baseline) and at the end of 4, 8, 12, 16 and 24 weeks.
- Secondary Outcome Measures
Name Time Method ilTimepoint: Nil